The membrane water channel aquaporin 5 (AQP5) plays an important role in transporting water across the apical surface of the alveolar epithelium and the epithelia of submucosal glands in the upper airway and nasopharynx. It is thus a potentially important target for modulating the fluid content of upper airway and nasopharyngeal secretions in disorders such as cystic fibrosis. Here, we have used an in vitro system to identify a molecular mechanism through which transcriptional and post-transcriptional regulation of AQP5 is accomplished. In a murine lung epithelial cell line (MLE-12), the addition of chlorophenylthio-cAMP (cpt-cAMP) causes a 4-fold increase in AQP5 mRNA and protein levels and induces translocation of AQP5 to the apical plasma membrane. Treatment with forskolin and isoproternol also caused similar increases in AQP5 expression both in vitro and in mouse lung tissue slices. The addition of actinomycin D abolished the cAMP-mediated increase in AQP5 mRNA and showed that there was no increase in the half-life of AQP5 mRNA, and inhibition of protein kinase A by H-89 blocked the cpt-cAMP-mediated increase of AQP5. Pretreatment of cells with cycloheximide blocked the cpt-cAMP-mediated increase of AQP5 mRNA, indicating that de novo protein synthesis is essential for increased AQP5 transcription. Immunofluorescent micrographs of cells treated with cpt-cAMP showed a significantly stronger AQP5 signal at the plasma membrane as compared with untreated cells. These results show that cAMP regulates AQP5 at multiple levels, by increasing synthesis of AQP5 mRNA and by triggering translocation of AQP5 to the plasma membrane.
Studies in animal models have shown that the AQP5 1 membrane channel plays a critical role in maintaining normal physiological function. Targeted deletion of AQP5 in mice results in lethality to 75% of the AQP5Ϫ/Ϫ embryos (1, 2) . In the one of four AQP5Ϫ/Ϫ embryos that survive to adulthood, absence of AQP5 results in a 10-fold decrease in osmotic water permeability of the airspace-capillary barrier (3, 4) , increased bronchoconstriction of the airways in response to cholinergic agonists (5) , and greatly reduced membrane water permeability in the epithelia of the submucosal glands of the upper airway and nasopharynx (6) . Indeed, the crucial role played by AQP5 as the rate-limiting barrier to water movement in the serous epithelial cells of submucosal glands has prompted speculation that modulation of the activity of AQP5 may provide a novel modality for treatment of infections that cause excessive fluid secretion in the upper airway and nasopharynx or provide a potential target for pharmacological intervention in diseases such as cystic fibrosis where gland secretions have decreased fluid content (6) .
In humans, deficiencies in proper expression or localization of AQP5 have also been associated with defects in water handling: for example, mutations in AQP5 that result in incorrect subcellular localization of the channel in the apical plasma membrane have been detected in individuals with Sjogren's syndrome, a disorder that includes decreased salivary and lachrymal secretions (7, 8) . Sufficient expression and proper subcellular targeting of AQP5 channels are therefore necessary for normal physiological function. Thus, the identification of molecular mechanisms that regulate the activity of AQP5 in lung epithelia will likely yield useful insights into the physiological properties of tissue and organ systems in which AQP5 is expressed.
Several lines of evidence prompted us to investigate the possibility that one of the mechanisms regulating AQP5 expression might involve cAMP. It has been shown previously that AQP2, the major renal water channel, is regulated by a vasopressin/cAMP pathway in the collecting duct of the kidney. Stimulation of the vasopressin V2-receptor by arginine-vasopressin results in increased AQP2 mRNA levels (9) and increased translocation of AQP2 to the plasma membrane (10) via a cyclic AMP (cAMP) pathway (11) . Increased expression of AQP1 in Xenopus oocyte membranes in response to cAMP and vasopression has also been demonstrated (12) , and more recently, translocation of AQP8 to the plasma membrane of hepatocyte cell lines in response to cAMP has been reported (13) .
The objective of this study was to identify molecular mechanisms that could regulate AQP5 expression. We developed an in vitro system in which the effect of cpt-cAMP on AQP5 mRNA and protein levels could be studied. Immunofluorescence microscopy was used to study the effect of cpt-cAMP on subcellular distribution of AQP5 protein. The time course for induction of both AQP5 mRNA and protein expression was determined, and the dose response to different concentrations of cpt-cAMP was studied. The effect of adding inhibitors of RNA transcription, protein synthesis, or phosphorylation by protein kinases A and C on the expression of AQP5 was investigated, as was the effect of forskolin and the ␤-adrenergic agonist isoproternol. Furthermore, we show that the addition of forskolin to freshly excised slices of mouse lung results in an increased level of AQP5 protein, corroborating the observations in vitro. These findings demonstrate a potentially important role for cAMP in regulating AQP5 at multiple levels and identify components of a molecular mechanism by which this membrane channel is regulated in lung epithelial cells.
MATERIALS AND METHODS
Experimental Reagents-cpt-cAMP, actinomycin D (ActD), forskolin, and isoproterenol (ISO) were obtained from Sigma. Dihydrochloride (H-89) and cycloheximide were obtained from Calbiochem. ActD, forskolin, and H-89 were dissolved in dimethyl sulfoxide (Me 2 SO). ISO was dissolved in 10 Ϫ4 M L-ascorbic acid. Cycloheximide was dissolved in 70% ethanol, and others were dissolved in double distilled water (ddH 2 O). RPMI 1640 medium with L-glutamine, fetal bovine serum, and antibiotics-antimycotics were obtained from Invitrogen. The antibody to ␤-actin was an anti-mouse monoclonal antibody purchased from Sigma. Anti-mouse AQP5 polyclonal antibody (LL639, Lofstrand Labratories, Gaithersburg, MD) was generated against a synthetic peptide corresponding to the mouse AQP5 carboxyl terminus and affinity-purified on a SulfoLink column (Pierce) conjugated with the immunizing peptide (14) . The horseradish peroxidase-labeled secondary antibody was obtained from Amersham Biosciences. Protein assay reagent, 4 -15% linear gradient ready gel, and polyvinylidene difluoride membrane were purchased from Bio-Rad. Biotin-conjugated sheep anti-rabbit secondary antibody was obtained from Calbiochem, and Cy-2-conjugated streptavidin was purchased from Jackson ImmunoResearch.
Cell Culture-MLE-12 cells were a gift from Dr. Jeffrey Whitsett (Children's Hospital Medical Center, Cincinnati, OH) (15) . MLE-12 cells were grown in RPMI 1640 (with L-glutamine) supplemented with 3% fetal bovine serum and 1% antibiotics-antimycotics at 37°C with 5% CO 2. Cultures were fed with fresh medium two times weekly.
cpt-cAMP and cAMP Activator Treatment-Approximately 48 h before cpt-cAMP, forskolin, and ISO treatments, cells were seeded into 6-well tissue culture plates at 5 ϫ 10 5 cells/well and were serum-starved 24 h before the treatments by replacing the medium with RPMI 1640 containing 1% fetal bovine serum as described by Towne et al. (16) . After 24 h of starvation, the medium was replaced with normal growth medium, and different concentrations of cpt-cAMP, forskolin, or ISO were added. Cells were then maintained in the medium for the duration of the experiment. Every experiment was repeated in its entirety at least twice in either duplicate or triplicate.
Actinomycin D Treatment-To determine the stability of AQP5 mRNA with or without cpt-cAMP, MLE-12 cells were treated for 4 h with 200 M cpt-cAMP, and then 10 g/ml ActD was added. For the inhibition of transcription, 10 g/ml ActD was added to the culture medium for 30 min before adding 200 M cpt-cAMP. Cells were collected, and total RNA was isolated at the indicated time points.
Cycloheximide and H-89 Treatment-To inhibit protein synthesis, cells were incubated with 500 g/ml cycloheximide, a dose sufficient to block protein synthesis by Ͼ98% (17), for 30 min before adding cptcAMP. To inhibit PKA activity, H-89 (30 M) was added to the culture medium for 30 min prior to the addition of cpt-cAMP. Total RNA and protein were isolated from the cells at the indicated times.
Total Protein Preparation and Protein Assay-Following each of the treatments described above, medium was aspirated, and the cells were washed with ice-cold phosphate-buffered saline. 500 l of ice-cold isolation buffer (pH 7.6), containing 250 mM sucrose, 10 mM triethanolamine, 1 g/ml leupeptin, and 0.1 mg/ml phenylmethylsulfonyl fluoride was added to each well for three successive freezing and thawing cycles in a dry ice/ethanol bath and 37°C water bath. Total protein concentrations were determined by the Bio-Rad CB-250 dye binding technique according to the modifications of Stoscheck (18, 19) , using bovine serum albumin as the standard.
Western Blot Analysis-6 g of total proteins was loaded per well in a 4-15% linear gradient SDS-polyacrylamide gel. After gel electrophoresis, proteins were transferred to polyvinylidene difluoride membrane. The membranes were blocked for 1 h at room temperature in 1% blocking solution (Roche Applied Science) followed by incubation overnight at room temperature with anti-AQP5 antibody at a dilution of 0.25 g/ml and anti-␤-actin antibody at a dilution of 1:50,000 in 0.5% blocking solution. Horseradish peroxidase-labeled anti-mouse and antirabbit secondary antibodies were incubated for 1 h at room temperature in 0.5% blocking solution. Immunoreactivity was detected by SuperSignal West Pico chemiluminescent reagents (Pierce). The protein in each band was quantified by using an AlphaImager 2000 documentation and analysis system (Alpha Innotech Corp., San Leandro, CA). Results are expressed as the ratio of AQP5/␤-actin.
RNA Isolation and Northern Blot Analysis-Total RNA was isolated from MLE-12 cells using TriReagent solution (Molecular Research Center, Inc., Cincinnati, OH) according to the manufacturer's instructions. RNA was solubilized in Formazol (Molecular Research Center, Inc.), and RNA concentrations were determined by spectrophotometry and confirmed by agarose gel electrophoresis. 10 g total RNA of each sample was size-fractionated in 1% formaldehyde agarose gel and transferred to Hybond N ϩ nylon membrane as described (20) . Hybridization and washing were performed as described by Towne et al. (20) . After probing with AQP5, the membranes were stripped in boiling 0.5% SDS for 30 min and were reprobed with p 32 -labeled L32, the gene encoded a ribosomal protein, as a control for equal loading of mRNA per well. The generation of mouse AQP5 and L32 probes was described previously (20) . The density of bands from Northern blots probed with either AQP5 or L32 was quantified using a Storm 840 PhosphorImager, and analyzed using ImageQuant software (Amersham Biosciences). Phosphorimaging results are reported as volume-integrated value. mRNA values are reported as the AQP5/L32 ratio for each sample.
Immunofluorescence Studies-MLE-12 cells were seeded onto 8-well Lab-Tek chamber slides (Nunc, Naperville, IL) at 3 ϫ 10 4 cells/well in 3% fetal bovine serum/RPMI 1640 medium for 24 h. Then cells were starved for 24 h by replacing the medium with 1% fetal bovine serum. After starving, the culture medium was replaced by normal growth medium (3% fetal bovine serum), and 200 M cpt-cAMP was added to the medium. Control wells were only treated with vehicle (ddH 2 O). 24 h later, cells were fixed for 10 min with 5% neutral buffered formalin and permeabilized with 100% methanol for 3 min. After blocking with 5% normal sheep serum, cells were incubated for 1 h at room temperature with anti-mouse polyclonal antibody (2 g/ml) diluted in phosphatebuffered saline containing 1% bovine serum albumin. Unbound antibody was removed by washing three times with phosphate-buffered saline/bovine serum albumin, and then cells were incubated for 45 min with biotin-conjugated sheep anti-rabbit secondary antibody (1:500 dilution) at 37°C. Following washing, cells were incubated with Cy-2-conjugated Streptavidin (1:150 dilution) for 20 min. Finally, the cells were mounted onto glass slides with ProLong antifade mounting solution (Molecular Probes). The samples were examined with a Zeiss LSM 510 upright confocal microscope (Zeiss, Oberkochen, Germany) using a C-Apochromat ϫ63, 1.2 water immersion objective.
Ex Vivo Studies on Excised Mouse
Lung-Approximately 50 mg of lung tissue was excised from euthanized C57/Black 6 mice, rinsed in serum-free RPMI 1640 medium, and placed in a tissue culture dish containing serum-free RPMI 1640 medium. A bolus of forskolin dissolved in Me 2 SO was added so that the final concentration of forskolin was 10 g/ml in medium. The tissue was incubated at 37°C in 5% CO 2 for 24 h, after which it was snap-frozen in liquid nitrogen and processed for total cellular protein as described earlier.
RESULTS

cpt-cAMP Increases AQP5 Protein Expression in MLE-12
Cells-The MLE-12 murine lung epithelial cell line (15) is a well characterized cell model for the expression and regulation of epithelial membrane proteins and was therefore chosen to investigate the effect of cpt-cAMP on AQP5 expression. To examine whether the response to cpt-cAMP was in a dose-dependent manner, MLE-12 cells were treated with 10, 20, 30, 50, 100, 200, 400, and 800 M cpt-cAMP for 48 h, respectively. Samples were then harvested, and total protein was prepared for immunoblot analysis. AQP5 protein levels increased in a dose-dependent manner in response to treatment with 20 -200 M cpt-cAMP (Fig. 1) . AQP5 protein was increased 2-and 4-fold in response to 20 and 50 M cpt-cAMP as compared with untreated control, and since the physiological range of cAMP concentration in mammals is 0.1-50 M (21), our findings suggest a potential physiological regulatory mechanism for AQP5. The lower limit for detection of the cpt-cAMP effect was 20 M, and the maximal induction of AQP5 (5-fold) was attained at a cAMP Regulation of AQP5cpt-cAMP concentration of 200 M in the medium. To detect the maximal effect, 200 M cpt-cAMP was used for all subsequent experiments.
To examine the time course of the cpt-cAMP effect on AQP5 protein levels, MLE-12 cells were treated with 200 M cptcAMP for 1, 3, 6, 24, 48, 72, and 96 h. A 2-fold increase in AQP5 protein was seen 3 h after treatment with cpt-cAMP, and the effect was maximal (5-fold increase) at 48 h (Fig. 2) . Beyond 48 h (72 and 96 h), a decrease in the cpt-cAMP effect (Fig. 2) was observed, but this decrease may be more difficult to interpret, possibly due to cellular adaptation to prolonged exposure to cAMP.
cpt-cAMP Increases AQP5 mRNA Level in MLE-12
Cells-To analyze the effect of cpt-cAMP on AQP5 mRNA expression, MLE-12 cells were treated with 200 M cpt-cAMP for 1, 3, 6, 24, 48, 72, and 96 h, respectively. Total RNA was isolated, and Northern blot analysis was performed as described under "Materials and Methods" (Fig. 3) . AQP5 mRNA level was increased 1.5-fold after 1 h of treatment. After 3 or 6 h treatment, AQP5 mRNA level was increased 3-fold as compared with untreated controls. Beyond 24 h, the trend of increasing AQP5 mRNA by cpt-cAMP was saturated, but the levels were still higher than controls.
The Increase of AQP5 mRNA Expression by cpt-cAMP Is Not Due to an Increase in mRNA Stability-To determine whether the increased AQP5 mRNA level is due to a decrease of AQP5 mRNA degradation, the stability of AQP5 mRNA was measured in the presence of the transcriptional inhibitor ActD. Cells were treated with 200 M cpt-cAMP or vehicle for 4 h, after which 10 g/ml ActD was added. Total RNA was isolated at 0, 1, 2, 4, and 6 h after the addition of ActD and analyzed by Northern blot (Fig. 4) . With AQP5 transcription blocked by actinomycin D, the levels of mRNA both with or without cpt- cAMP Regulation of AQP5cAMP were decreased as compared with mRNA from the 0 h time point. The mRNA in the cpt-cAMP-treated group did not show lower turnover (which would be reflected in a decreased slope) than in the cpt-cAMP-untreated controls. The degradation of cpt-cAMP-treated mRNA showed a slight, but not statistically significant, increased turnover as compared with the samples that were not treated with cpt-cAMP, showing that increased AQP5 mRNA level in response to cpt-cAMP is not due to an increase in AQP5 mRNA stability.
The cpt-cAMP-induced Increase in AQP5 mRNA Levels Is Due to Increased Transcription-Based on the observation that cpt-cAMP did not affect the stability of AQP5 mRNA, we hypothesized that the increased AQP5 mRNA by cpt-cAMP was due to increased transcription of the AQP5 gene. To test this hypothesis, MLE-12 cells were first treated with either ActD (10 g/ml) or vehicle (Me 2 SO) for 30 min to inhibit transcription and then with 200 M cpt-cAMP for 3 h. RNA prepared from these cells was analyzed by Northern blot (Fig. 5) . In the absence of ActD, cpt-cAMP treatment increased AQP5 mRNA levels about 4 -5-fold. Pretreatment with actinomycin D completely blocked the ability of cpt-cAMP to increase AQP5 mRNA. This shows that the increased level of AQP5 mRNA in response to treatment of cpt-cAMP is principally due to increased transcription of the AQP5 gene. (Fig. 6, A and B) showed that pretreatment with H-89 inhibited about 60% of the effect of cpt-cAMP on AQP5 mRNA. Western blot analysis showed that (Fig. 6, C and D) H-89 completely abolished the effect of cpt-cAMP on increased expression of AQP5 protein. Although H-89 did not completely block the effect of cpt-cAMP on AQP5 at mRNA level, it totally abolished the effect of cpt-cAMP on AQP5 at protein level, indicating that the activity of protein kinase A affects the expression of AQP5 at both transcriptional and post-transcriptional levels. The action of cpt-cAMP on AQP5 expression is due to increasing the activity of protein kinase A. Phorbol 12-myristate 13-acetate did not show any effect on the expression of AQP5 protein (data not shown), suggesting that protein kinase C may not be involved in the regulation of AQP5 in lung epithelial cells.
Protein Kinase A Inhibitor H-89 Blocks the cpt-cAMP-mediated Increase in AQP5 in
The Effect of cpt-cAMP on AQP5 mRNA Expression Depends on de Novo Protein Synthesis-To investigate whether the new synthesized nuclear factors are required for the effect of cptcAMP on the transcription of the AQP5 gene, MLE-12 cells were pretreated with cycloheximide (500 g/ml) for 30 min to inhibit protein synthesis, and 200 M cpt-cAMP was added. Total RNA was isolated at two time points, 3 or 6 h, after the addition of cpt-cAMP. The expression of AQP5 mRNA detected by Northern blotting (Fig. 7, A and B) showed that cycloheximide inhibited about 70% of the increase of AQP5 mRNA induced by cpt-cAMP in both 3 and 6 h treatments. Cycloheximide alone did not affect the expression of AQP5 mRNA (Fig.  7B) and protein (Fig. 7D) . Therefore, the effect of cpt-cAMP on AQP5 requires de novo protein synthesis to stimulate the transcription of the AQP5 gene. 
cAMP Regulation of AQP5
The Effect of cpt-cAMP on the Distribution of AQP5 ProteinSince AQP5 has a protein kinase A-binding site in loop D, which is similar in AQP2 (23), we hypothesized that cAMP might influence the distribution of AQP5 protein. To test this hypothesis in MLE-12 cells, immunofluorescence was employed. Cells were treated with 200 M cpt-cAMP for 24 h, and then immunofluorescent staining was performed, and the samples were examined by a confocal microscope as described under "Materials and Methods." Cells treated with cpt-cAMP exhibited stronger staining of AQP5 in plasma membrane (Fig.  8B ) as compared with control cells (Fig. 8A) , indicating that AQP5 is translocated to the plasma membrane in response to cpt-cAMP.
Both Forskolin and ISO Increase Expression of AQP5 Protein in MLE-12
Cells-Based on the observation that cpt-cAMP was found to increase levels of AQP5 mRNA and protein, we investigated whether an increase of endogenous cAMP stimulated by cAMP activators, such as forskolin and ISO, can also increase AQP5 expression. Forskolin, an activator of adenylyl cyclase (21) , and ISO, which activates the adenylyl cyclase through ␤-adrenergic receptor coupling with G protein (24, 25) , were chosen for these studies. Cells were either treated with forskolin at concentrations of 0.1, 1, and 10 g/ml or treated with ISO at concentrations of 1, 10, and 100 M. Total protein was prepared and analyzed by Western blots after 48 h. Our results, shown in Fig. 9, A and B , indicate that treatment with forskolin increased AQP5 protein levels 3-4-fold in a dose-dependent manner, and ISO induced a 2-fold increase in AQP5 protein level (Fig. 9, C and D) . The expression of ␤ 2 adrenoreceptor in MLE-12 cells was confirmed by [
125 I]cyanopindolol binding assay (data not shown). The combined results from the forskolin and ISO treatments show that an increase of endogenous cAMP induces a similar effect as that elicited by cptcAMP, and furthermore, that agonist stimulation of known physiological circuits, such as the ␤ 2 adrenoreceptor pathway, are capable of modulating the expression of AQP5 in lung cells.
Addition of Forskolin to Mouse Lung Tissue Slices ex Vivo Results in Increased Levels of AQP5
Protein-To determine whether the effects of cAMP on AQP5 that are observed in the MLE-12 cell line are recapitulated in lung tissue, we examined the effect of adding 10 g/ml forskolin on freshly excised lung tissue slices. The results of this experiment, shown in Fig. 10 , indicate that after incubation in medium containing forskolin for 24 h, the level of AQP5 protein was increased 2-fold, showing that the action of forskolin on AQP5 in the ex vivo lung corroborates its action on AQP5 in vitro.
DISCUSSION
The objective of this study was to identify molecular signaling pathways that regulate the expression of AQP5 in epithelial cells of the lung. Our decision to first investigate mechanisms involving cAMP was prompted by considerable physiological and cell biological evidence showing that stimulation of the V2 vasopressin receptor in the kidney results in translocation of AQP2 to the plasma membrane via a cAMP mechanism (26) . We also noted that the original observation by King and Agre (23) of a PKA consensus sequence in a cytoplasmic loop of AQP5 at amino acid residues 153-156 (Arg-ArgThr-Ser) would likely be consistent with a cAMP mechanism for the regulation of AQP5.
Using an in vitro system of mouse lung epithelial cells (MLE-12), we found that treatment with cpt-cAMP had two distinct effects on AQP5: first, it resulted in a 3-fold increase in AQP5 mRNA and a 5-fold increase in protein levels, and second, it resulted in a significant increase in the density of AQP5 channels in the plasma membrane, detected by immunofluorescence cAMP Regulation of AQP5microscopy. Our subsequent studies were directed at identifying the molecular mechanisms underlying these effects.
cpt-cAMP increased AQP5 protein 5-fold in a dose-and timedependent manner (Figs. 1 and 2) . Although increased AQP5 levels were detected using as little as 20 M cpt-cAMP, the maximal effect was observed at 200 M cpt-cAMP in the cell culture medium. The concentrations of cpt-cAMP (10 -50 M) over which the effect on AQP5 is seen in MLE-12 cells suggests that the action of cpt-cAMP operates within the range of normal variation in cellular concentrations of cAMP.
cpt-cAMP also increased AQP5 mRNA expression 3-5-fold (Figs. 3 and 5 ). As might be expected, the increased levels of APQ5 mRNA in response to cpt-cAMP were detectable somewhat earlier than protein. The maximal increase in AQP5 mRNA level was observed between 3 and 6 h after cpt-cAMP treatment, but the maximal increase in AQP5 protein (prepared from whole cell extracts) was seen only at 48 h, indicating that increased protein levels most likely resulted from translation of increased numbers of AQP5 mRNA transcripts.
To determine whether increased numbers of AQP5 mRNA transcripts were the consequence of increased AQP5 transcription or increased stability of AQP5 mRNA, cells were incubated with the RNA polymerase II inhibitor, ActD, prior to stimulation with cpt-cAMP (Fig. 5 ). This completely abolished the effect of cpt-cAMP on the AQP5 mRNA (Fig. 5) , indicating that the increase in AQP5 mRNA levels was a result of increased AQP5 gene transcription rather than a decrease in the turnover rate of AQP5 mRNA or increased stability of the mRNA transcript.
Based on published reports that cAMP frequently regulates the transcription of target genes by protein kinase A (PKA)-dependent phosphorylation of cAMP-responsive element-binding protein, thus modulating the affinity of cAMP-responsive element-binding protein for cAMP-responsive elements in the target gene (27, 28) , we asked whether the effect of cpt-cAMP on AQP5 expression involved PKA. We found that pretreatment of cells with H-89, an inhibitor of PKA, prior to the addition of cpt-cAMP totally abolished the increase in AQP5 mRNA and protein levels (Fig. 6) , indicating that the action of PKA is necessary for the transcriptional increase of AQP5 induced by cAMP, most likely through the phosphorylation of one or more transcription factors. To further dissect the pathway connecting the agonist, cpt-cAMP, with its transcriptional target, AQP5, we asked whether synthesis of transcriptional factors was required for the agonist-mediated increase in transcription of the target gene. Incubation of cells with the protein synthesis inhibitor cycloheximide prior to adding cpt-cAMP substantially blocked (by about 70%) the increase in AQP5 mRNA (Fig. 7) . To our knowledge, this is the first evidence showing that de novo protein synthesis of specific transcriptional factor(s) is essential for the effect of cAMP on any aquaporin.
To determine whether triggering an increase of endogenous cAMP evoked the same response in AQP5 as the addition of cpt-cAMP, we stimulated cellular adenylyl cyclase activity by the addition of either forskolin or the ␤-adrenergic agonist ISO. We found that the addition of forskolin (Fig. 9, A and B) and ISO (Fig. 9, C and D) resulted in an increased level of AQP5 protein, indicating that physiological circuits that are known to exist in the lung (24) can be triggered by appropriate agonists to modulate AQP5 expression. To further investigate whether the effects seen in MLE-12 cells were corroborated in lung tissue, we added forskolin to freshly excised slices of mouse lung and examined its effect on AQP5 after 24 h of treatment. The data from this experiment, shown in Fig. 10 , indicate that treatment with forskolin results in a 2-fold increase in AQP5 protein. Although the increase in AQP5 protein in lung tissue is less than the 5-fold increase observed in the MLE-12 cell line, and this is probably due to the heterogeneity of the cell types in the mouse lung, the data clearly demonstrate that stimulation One of the important cellular mechanisms by which membrane channels are rapidly mobilized consists of trafficking channel proteins from cellular reservoirs to the plasma membrane in response to appropriate stimuli. For example, it has been shown that water permeability in the renal collecting duct is primarily regulated by vasopressin-mediated translocation of the AQP2 water channel to the luminal plasma membrane in the epithelia of the collecting duct (11, 26) . To test whether cpt-cAMP triggered a similar translocation of AQP5 to the plasma membrane, we used immunofluorescence staining with AQP5 antibody to examine the localization of AQP5 in lung epithelial cells that were treated with 200 M cpt-cAMP and untreated controls. The data clearly demonstrate that treatment with cpt-cAMP results in translocation of AQP5 to the plasma membrane (Fig. 8) . Although the staining did not unequivocally reveal whether the translocation of AQP5 was exclusively to the apical surface or to both apical and basolateral surfaces, we found that AQP5 in MLE-12 cells is detected predominantly in a punctate intracellular pattern and was not visibly detectable in the plasma membrane in untreated cells. However, treatment with cpt-cAMP resulted in a significant translocation of AQP5 from intracellular reservoirs, possibly subplasma membrane vescicles, to the plasma membrane (Fig.  8) , indicating that a cAMP-triggered mechanism for translocation to the plasma membrane is apparently shared by both AQP5 (in the lung) and AQP2 in the renal collecting duct (29, 30) . These findings may be particularly relevant to pharmacological approaches to treatment of hyperviscous secretions in cystic fibrosis because they reveal components of a molecular mechanism that can potentially regulate the activity of AQP5, which is the rate-limiting step in determining the fluid content of secretions from the submucosal glands of the upper airways and nasopharynx. 
